Why Delhi High Court Drew a Hard Line on Diabetes Drug Combinations

Scale of Impact: How Large Is the Diabetes Drug Market Affected?

India’s type-2 diabetes burden gives this ruling an economic and public-health scale that goes far beyond the specific drug combinations under challenge. According to estimates by the International Diabetes Federation (IDF), India currently has around 101–105 million adults living with diabetes, a figure projected to rise to over 130 million by 2045, making it the single largest diabetes market globally.

Oral anti-diabetic drugs form the backbone of treatment for early and mid-stage type-2 diabetes, accounting for an estimated 60–65% of prescriptions, before patients transition to insulin-based regimens. Within this space, fixed-dose combinations have historically occupied an outsized commercial footprint, not because of superior clinical outcomes, but due to aggressive marketing, prescribing convenience, and simplified dosing narratives.

Industry data and prescription audits cited in regulatory discussions suggest that FDCs—particularly dual and triple combinations—have, at various points, accounted for 20–30% of oral anti-diabetic prescriptions in certain urban and semi-urban markets. Triple-drug combinations, while narrower in volume, are often positioned for long-term use in patients with poor glycaemic control, magnifying downstream safety implications.

The practical consequence of the ban, therefore, is not marginal. It directly affects millions of prescriptions annually, forces a return to individually titrated therapies, and reshapes prescribing behaviour across one of India’s fastest-growing chronic disease segments. The court’s insistence on safety over convenience thus operates at population scale, not merely at the margins of pharmaceutical regulation.

The Long Regulatory Trail: From Mass Bans to Supreme Court Oversight

The case has its roots in 2016, when the central government imposed a sweeping ban on 344 fixed-dose combinationsfollowing recommendations of the Kokate Committee, which found many of them to be irrational, unsafe, or lacking therapeutic justification. The pharmaceutical industry challenged the bans across multiple high courts, arguing that the government had acted arbitrarily and without adequate hearing.

The legal battle culminated in Union of India v. Pfizer Limited (2017), where the Supreme Court ordered a fresh, drug-by-drug scientific review. The Court directed the Drugs Technical Advisory Board (DTAB) to constitute a specialised sub-committee and evaluate each FDC on three precise statutory criteria:

• Whether the drug is likely to involve risk to humans,
• Whether it lacks therapeutic value, and
• Whether it contains ingredients without therapeutic justification.

This framework became the legal and scientific foundation for all subsequent regulatory action.

Expert Review: Why the Triple Combination Failed

Pursuant to the Supreme Court’s directions, a DTAB sub-committee undertook an extensive review of the triple-drug diabetes combinations. The panel examined 395 scientific publications, heard detailed submissions from pharmaceutical manufacturers, and considered evidence from public-health organisations including the All India Drug Action Network (AIDAN).

The committee unanimously recommended a complete ban, identifying two core deficiencies. First, it found a material risk of hypoglycaemia, given the cumulative glucose-lowering effect of the three drugs when administered together. Second, it noted the absence of combination-specific clinical safety data. Manufacturers relied almost entirely on studies relating to the individual drugs, but failed to produce controlled trials demonstrating that the three-drug combination was safe and effective as a single formulation.

The committee also recorded that such triple-drug FDCs are not approved or routinely accepted by major international drug regulators, further undermining claims of global best practice.

Global Regulatory Context: How Other Jurisdictions Treat Fixed-Dose Combinations

The Delhi High Court’s reasoning aligns closely with how major global drug regulators approach fixed-dose combinations, particularly those involving multiple metabolic agents.

In the United States, the Food and Drug Administration (FDA) treats fixed-dose combinations as new drugs for approval purposes, even when all constituent active pharmaceutical ingredients are individually approved. Sponsors are required to submit combination-specific clinical trials, including dose-finding studies, pharmacokinetic interaction data, and evidence that the fixed combination offers either superior efficacy or a demonstrable safety advantage over separate administration.

Similarly, the European Medicines Agency (EMA) mandates that combination drugs establish a clear therapeutic justification, demonstrating that the fixed formulation improves outcomes, safety, or adherence without introducing new risks. The EMA’s guidance explicitly warns against combinations that reduce clinicians’ ability to individualise dosing in chronic diseases such as diabetes.

As a result of these standards, triple-drug oral anti-diabetic combinations of the kind banned in India are not routinely approved or marketed in tightly regulated Western jurisdictions. Where combinations are permitted, they typically involve well-studied dual therapies with extensive post-marketing surveillance data.

Against this backdrop, the DTAB sub-committee’s concern—that manufacturers relied solely on the safety profiles of individual drugs without producing combination-specific evidence—mirrors international regulatory logic. The Indian position, as affirmed by the High Court, is therefore convergent with global best practice, rather than unusually restrictive or protectionist.

2019: How the Ban Was Diluted

Despite these findings, a single-judge bench of the Delhi High Court in February 2019 quashed the government’s notifications. The judge held that since all three medicines were individually approved and recommended in diabetes treatment guidelines, banning their combination was arbitrary. The court gave significant weight to patient convenience, reasoning that taking one pill instead of three improved compliance.

The matter was remanded to the DTAB for reconsideration, which had the practical effect of allowing the drugs to remain on the market during the interregnum.

Division Bench Reversal: Reasserting the Limits of Courts

The central government and AIDAN appealed, and the Division Bench delivered a detailed 46-page judgment decisively overturning the 2019 order. The court held that the single-judge bench had exceeded the permissible limits of judicial review by independently analysing scientific literature and effectively sitting in appeal over an expert regulatory body.

The Division Bench emphasised that judges are “institutionally ill-equipped” to determine issues of pharmacology, dosage optimisation, and drug-interaction risk. Once a duly constituted expert committee has undertaken a reasoned scientific evaluation, courts cannot replace that assessment with judicial interpretation of research papers.

Section 26A: Acting Before Harm Occurs

A central pillar of the ruling is the court’s interpretation of Section 26A of the Drugs and Cosmetics Act, 1940. The Bench clarified that the provision empowers the government to act preventively, not merely reactively. The law does not require proof of actual harm before a ban can be imposed.

“The statutory standard,” the court held, “does not require the establishment of actual or proven injury to human beings.” Instead, the focus is on potential or foreseeable risk arising from continued use of the drug. Waiting for deaths or hospitalisations, the court warned, would defeat the protective purpose of the regulatory framework.

Convenience Cannot Trump Safety

The Division Bench squarely rejected the “convenience” argument that had persuaded the single-judge bench. While acknowledging that a single pill may be easier for patients to consume, the court ruled that ease of administration cannot override safety considerations. Under Indian law, every FDC is categorised as a new drug, and manufacturers carry a non-negotiable statutory burden to prove its safety and efficacy through appropriate data—an obligation that remained unmet in this case.

Precedent Value: What the Judgment Means for Future Drug Challenges

Beyond the immediate ban, the judgment carries significant precedential weight for pending and future challenges to drug prohibitions under Section 26A of the Drugs and Cosmetics Act.

First, it raises the evidentiary bar for pharmaceutical companies seeking judicial relief against expert-backed bans. The ruling makes clear that courts will not grant protection merely because individual ingredients are approved or widely prescribed. Combination-specific safety and efficacy data will now be central, not peripheral, to judicial scrutiny.

Second, the judgment is likely to influence ongoing and future litigation involving other fixed-dose combinations, including recent bans on widely used fever, cold, and cough formulations. By reaffirming that the government can act on foreseeable risk, the court has strengthened the Centre’s hand in defending preventive bans even in the absence of documented patient harm.

Third, the decision sharply reduces the scope for interim relief based on arguments of commercial disruption or patient convenience. Manufacturers will find it harder to keep products on the market during prolonged litigation if expert bodies have already flagged safety concerns.

In effect, the ruling resets the litigation equilibrium: regulatory science, once validated through a statutory expert process, will enjoy strong judicial deference, while pharmaceutical challenges will increasingly turn on procedural flaws rather than substantive re-evaluation of medical evidence.

What the Judgment Changes

By restoring the ban with immediate effect, the Delhi High Court has:

• Reinforced the primacy of expert scientific bodies in drug-approval decisions,
• Clarified that courts must exercise restraint in matters involving complex medical science, and
• Strengthened the Centre’s authority to act pre-emptively to protect public health.

For pharmaceutical companies, the ruling signals a tougher compliance environment for fixed-dose combinations and a higher evidentiary bar for market approval. For patients and clinicians, it underscores a regulatory philosophy that places evidence-based safety above convenience, even in a country with a massive and growing burden of type-2 diabetes.